AbCellera Q1 2022 revenue $317M, net earnings $0.59/sh, up from $0.43/sh YoY

AbCellera Biologics Inc.

2022-Q1 EPS reported $0.54 revenue$316,581,000

Total revenue $316.6M (up 56% YoY from $202.7M); net earnings $168.6M ($0.59 basic EPS vs $0.43).
Royalties from bamlanivimab/bebtelovimab contributed $307M of total revenue.
Cumulative program starts reached 84 (up 56% YoY); discovery partners grew to 36 from 29.
Cash, cash equivalents and marketable securities stood at $786.1M.
R&D expenses rose to $26.4M from $12.4M YoY, driven by platform investment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.